ABECMA

Registered
Word Mark

Key Information

Serial Number

Registration Number

Status

Registered

Ownership

CC

Owner Name

Type: Organization / Corporation

Address

86 Morris Ave
Summit, NJ 07901

Critical Dates

First Use Date

Mar 26, 2021

Filing Date

Nov 5, 2020

Registration Date

Sep 13, 2022

Mark Descriptions

Services

Class 44
Medical treatment services in the fields of multiple myeloma, cancer, and diseases in the fields of oncology; provision of medical information and data for diagnosis and medical treatment

Mark Elements

Text Mark
ABECMA
Category
Service Mark
Standard Characters
Yes
Color Claim
No
Data source: USPTO TSDR
View on USPTO website

Trademark Timeline

First Use

Mar 26, 2021

Filing Date

Nov 5, 2020

Publication Date

Nov 23, 2021

Registration Date

Sep 13, 2022

USPTO Records

Title
Date
Category
Source
Pages
Format
Actions
Notice of Registration-Notice
NOTRG(8 KB)
Sep 13, 2022
Outgoing
CMS
1
PDF
Registration Certificate
ORC(316 KB)
Sep 13, 2022
Outgoing
CMS
1
PDF
TRAM Snapshot of App at Pub for Oppostn (Part 1)
PST
Aug 6, 2022
TRAM Snapshot
TICRS
2
XML
TRAM Snapshot of App at Pub for Oppostn (Part 2)
PST
Aug 6, 2022
TRAM Snapshot
TICRS
2
JPEG
Notice of Acceptance of Statement of Use
ASU
Aug 6, 2022
Outgoing
TICRS
1
XML
ITU Unit Action (Part 1)
IUA
Aug 2, 2022
TRAM Snapshot
TICRS
2
XML
ITU Unit Action (Part 2)
IUA
Aug 2, 2022
TRAM Snapshot
TICRS
2
JPEG
Statement of Use (Part 1)
SOU
Jul 12, 2022
Incoming
TICRS
6
XML
Statement of Use (Part 2)
SOU
Jul 12, 2022
Incoming
TICRS
6
JPEG
Statement of Use (Part 3)
SOU
Jul 12, 2022
Incoming
TICRS
6
JPEG
Statement of Use (Part 4)
SOU
Jul 12, 2022
Incoming
TICRS
6
JPEG
Statement of Use (Part 5)
SOU
Jul 12, 2022
Incoming
TICRS
6
JPEG
Statement of Use (Part 6)
SOU
Jul 12, 2022
Incoming
TICRS
6
TIFF
Specimen (Part 1)
SPE
Jul 12, 2022
Specimens
TICRS
4
JPEG
Specimen (Part 2)
SPE
Jul 12, 2022
Specimens
TICRS
4
JPEG
Specimen (Part 3)
SPE
Jul 12, 2022
Specimens
TICRS
4
JPEG
Specimen (Part 4)
SPE
Jul 12, 2022
Specimens
TICRS
4
JPEG
Notice of Allowance
ALW
Jan 18, 2022
Outgoing
TICRS
1
XML
OG Publication Confirmation
PB3
Nov 23, 2021
Outgoing
TICRS
1
XML
Notice of Publication
NOP
Nov 3, 2021
Outgoing
TICRS
1
XML
Notification Of Notice of Publication
NON
Nov 3, 2021
Outgoing
TICRS
1
XML
TRAM Snapshot of App at Pub for Oppostn (Part 1)
PST
Oct 22, 2021
TRAM Snapshot
TICRS
2
XML
TRAM Snapshot of App at Pub for Oppostn (Part 2)
PST
Oct 22, 2021
TRAM Snapshot
TICRS
2
JPEG
Public Note
PNR(5 KB)
Oct 21, 2021
Public Notes
CMS
1
PDF
Amendment and Mail Process Complete (Part 1)
AMC
Oct 21, 2021
TRAM Snapshot
TICRS
2
XML

AI AssessmentCached Mar 12, 2026, 06:36 AM
Cached

AI-generated analysis of USPTO data for this trademark. WARNING: Content may not be accurate or up to date. Validate all responses.

Trademark Summary

ABECMA is a standard character service mark for medical treatment services in the fields of multiple myeloma, cancer, and oncology diseases, plus provision of medical information and data for diagnosis and treatment in International Class 044. The mark is owned by Celgene Corporation, a Delaware corporation headquartered at 86 Morris Ave, Summit, New Jersey 07901. It is currently registered on the Principal Register (Registration No. 6847538) since September 13, 2022, with first use in commerce on March 26, 2021. No notable issues or legal proceedings are present.

Recent Activity

Filed on November 5, 2020, the application faced a non-final office action on April 19, 2021, followed by applicant's response and approval for publication on October 21, 2021. Published for opposition on November 23, 2021, it issued a Notice of Allowance on January 18, 2022; after submission of the Statement of Use on July 12, 2022, the mark registered on September 13, 2022.
USPTO
AI Analysis
v2.8.0
Generated Mar 12, 2026, 06:36 AM

Never miss important updates for this trademark

Get instant alerts when status changes, similar marks are filed, or renewal deadlines approach

Cookie Preferences

We use cookies (including Google Analytics) to improve our site and understand how visitors use it.